Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Pliant Therapeutics (PLRX) Gains from Sales and Divestitures (2019 - 2020)

Pliant Therapeutics has reported Gains from Sales and Divestitures over the past 2 years, most recently at $163568.0 for Q4 2020.

Quarterly Gains from Sales and Divestitures changed N/A to $163568.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $163568.0 through Dec 2020, changed N/A year-over-year, with the annual reading at $163568.0 for FY2020, N/A changed from the prior year.
Gains from Sales and Divestitures was $163568.0 for Q4 2020 at Pliant Therapeutics, up from $130257.0 in the prior quarter.
Over five years, Gains from Sales and Divestitures peaked at $335610.0 in Q3 2019 and troughed at $92199.0 in Q2 2020.